Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.
1/5 보강
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by late-stage diagnosis, resistance to conventional chemotherapy, and a dismal 5-year survival rate of approximately
APA
Xie C, Ke JJ, Liu FQ (2025). Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.. Hepatobiliary & pancreatic diseases international : HBPD INT. https://doi.org/10.1016/j.hbpd.2025.12.008
MLA
Xie C, et al.. "Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.." Hepatobiliary & pancreatic diseases international : HBPD INT, 2025.
PMID
41419408 ↗
Abstract 한글 요약
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by late-stage diagnosis, resistance to conventional chemotherapy, and a dismal 5-year survival rate of approximately 12 %. These challenges underscore the urgent need for more effective therapeutic strategies. Recent advances in the understanding of PDAC pathophysiology, combined with the successful implementation of targeted therapies and immunotherapies in other cancer types, offer promising avenues for improving PDAC outcomes. This review summarized the latest developments in targeted and immune-based therapies for PDAC. A comprehensive literature search was conducted using PubMed (MEDLINE) and Web of Science, identifying 36 studies on targeted therapies and 24 studies on immunotherapies relevant to PDAC. Several investigational and approved agents, including KRAS inhibitors (MRTX1133, sotorasib), PARP inhibitors (olaparib), and immune checkpoint inhibitors (pembrolizumab), have demonstrated encouraging results, particularly in combination regimens. These findings provide valuable insights into future research and clinical strategies aiming at improving the prognosis of PDAC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Inhibition of LDHA promotes GSDME-dependent pyroptosis by activating RIG-I-like receptor signaling.
- Synergistic Antitumor Activity and Neuroprotective Effects of FGF1/FGFR Inhibition with Oxaliplatin Chemotherapy.
- Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC.
- Diallyl Trisulfide Suppresses Tumor-Associated Macrophage M2-Like Polarization and Recruitment and Improves the Tumor Microenvironment Through Blocking CCL5/STAT3 Signaling Pathway Against Lung Cancer.
- A Perioperative Care Strategy for Prevention of Postoperative Delirium in Elderly Patients with Gastrointestinal Tumors: A Clinical Observational Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.